Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Study acronym: APS
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Mar 2028 to Mar 2029v34
  2. Primary and study completion dates: Dec 2024 to Mar 2028v33
  3. Primary and study completion dates: Dec 2023 to Dec 2024v32
  4. Primary and study completion dates: Dec 2022 to Dec 2023v31
  5. Primary and study completion dates: Dec 2021 to Dec 2022v30
Show 28 earlier versionsHide 28 earlier versions
  1. 2 versions Re-verified since Aug 3, 2020, no change to tracked fieldsv28-v29
  2. Primary and study completion dates: Dec 2019 to Dec 2021v27
  3. Primary completion date: Jul 2019 to Dec 2019v26
  4. Re-verified, no change to tracked fieldsv25
  5. Primary completion date: Jul 2018 to Jul 2019
    • Study completion date: Dec 2018 to Dec 2019
    v24
  6. Primary completion date: Jul 2017 to Jul 2018
    • Study completion date: Dec 2017 to Dec 2018
    v23
  7. Re-verified, no change to tracked fieldsv22
  8. Primary completion date: Jul 2016 to Jul 2017
    • Study completion date: Jul 2016 to Dec 2017
    v21
  9. Re-verified, no change to tracked fieldsv20
  10. Primary and study completion dates: Jul 2015 to Jul 2016v19
  11. 3 versions Re-verified since Apr 15, 2014, no change to tracked fieldsv16-v18
  12. Study Status, Sponsor/Collaborators, Outcome Measuresv15
  13. 2 versions Re-verified since Aug 16, 2011, no change to tracked fieldsv13-v14
  14. Lead sponsor: Office of Rare Diseases (ORD) to Duke Universityv12 Show 5 more changesShow less
    • Primary and study completion dates: Jul 2009 to Jul 2015
    • Study sites: 8 to 1
    • Eligibility criteria shortened, about 81 words
    • Collaborators shortened, about 12 words
    • Study arms: 2 to 3
  15. Re-verified, no change to tracked fieldsv11
  16. Site details revised at 2 of 8 sitesv10
  17. Study sites revised (8)v9
  18. Primary and study completion dates: Dec 2008 to Jul 2009
    • Study sites: 5 to 8
    v8
  19. Site details revised at 1 of 5 sitesv7
  20. Primary and study completion dates: Dec 2008v6
  21. Site details revised at 1 of 5 sitesv5
  22. Study Status, Sponsor/Collaborators, Study Design, Arms and Interventions, Eligibilityv4
  23. Re-verified, no change to tracked fieldsv3
  24. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 5 of 5 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Duke University
458 trials monitored
See 59 trials at risk
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
Trial Details
NCT Number NCT00482794
Lead Sponsor Duke University
Conditions
(from sponsor)		 Antiphospholipid Syndrome
Related terms Antiphospholipid Syndrome
Enrollment 2,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov